Ciclox

Quick links to important sections

Medically reviewed

Laura Arias

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Ciclox

Quick Facts

Property Description
Active ingredient Aciclovir (Acyclovir)
Form Tablet, Capsule, Oral Suspension, Topical Cream/Ointment, Intravenous Solution
Pharmacological class Antiviral Agent, Synthetic Nucleoside Analogue
Common use Control of infections caused by Herpes Simplex Virus and Varicella-Zoster Virus
Origin Synthetic Compound

What Type of Medicine is Ciclox?

Ciclox is the trade name for a highly specific antiviral medication whose active component is Aciclovir, also recognized as Acyclovir. This medicine is distinctly classified within the Synthetic Nucleoside Analogues pharmacological class, underscoring its role in combating infections caused by viruses. Aciclovir targets herpes viruses, establishing its use as a standard agent in managing these infections.

As a synthetic agent, Aciclovir serves a purpose by managing infections stemming from the Herpesvirus family, primarily the Herpes Simplex Virus (HSV) and Varicella-Zoster Virus (VZV). Its classification signifies that it is chemically distinct from antibiotics, focusing exclusively on viral control. The Ciclox brand is often noted for offering a comprehensive range of different pharmaceutical preparations.


Composition and Available Forms

The therapeutic effect of Ciclox is derived entirely from its single active component, Aciclovir, which is an acyclic purine nucleoside analogue. This medication is manufactured as a single-ingredient product and is available in multiple dosage forms to accommodate various sites of infection and patient needs.

These forms include tablets and capsules for oral intake, alongside topical cream or ointment for external application. For more severe systemic infections, a sterile solution for intravenous injection is available. The availability of Ciclox across oral, topical, and intravenous routes allows for tailored delivery of the Aciclovir compound.


General Benefit and Action Principle

The primary general benefit of Ciclox is its established ability to control the replication and spread of highly specific viral pathogens in the body. It operates on the principle of selective inhibition of viral replication, meaning it primarily interferes with the viral reproductive cycle inside infected cells.

This targeted action involves the medicine's unique conversion and subsequent interference with the virus's ability to copy its own DNA. By interrupting this process, the medication limits the proliferation of the Herpes Simplex Virus and Varicella-Zoster Virus, a mechanism recognized for contributing to the resolution of the acute episode.

Regulatory References

  1. NIH LiverTox: Acyclovir
  2. MedlinePlus: Acyclovir Drug Information

What side effects are possible with Ciclox?

Official Safety Profile and Adverse Reactions

The possible side effects of Ciclox (Aciclovir) are formally documented by government regulatory bodies and classified based on frequency of occurrence, primarily affecting specific body systems.

Classification Examples of Reactions
Common Headache, dizziness, nausea, vomiting, diarrhea, abdominal pains, pruritus, rashes, fatigue.
Uncommon Urticaria (hives), accelerated diffuse hair loss (uncertain relationship).
Rare Anaphylaxis, angioedema, dyspnoea, increases in blood urea and creatinine, and reversible rises in liver enzymes.
Very Rare Acute renal failure, hepatitis, jaundice, blood disorders (anaemia, leukopenia), and severe, generally reversible neurological reactions (e.g., confusion, convulsions, encephalopathy).

Serious adverse reactions officially noted include Anaphylaxis, Angioedema, and Acute Renal Failure. The regulatory safety profile also includes specific considerations for certain populations. Older adults and patients with renal impairment have a documented increased risk for developing neurological adverse effects and require particular caution. These neurological events are generally documented as reversible upon discontinuation. The medicine is formally contraindicated in individuals with known clinically significant hypersensitivity to aciclovir or valaciclovir.

Overdose and Emergency Response

Overdose and When to Seek Help

Overdose of Ciclox (Aciclovir) is primarily documented in regulatory sources to affect the Central Nervous System (CNS) and the Renal system. Clinical manifestations of overdose include neurological effects such as agitation, confusion, lethargy, hallucinations, and seizures. Gastrointestinal effects, including nausea and vomiting, are also documented, often following repeated high-dose oral exposure.


Serious Outcomes and Emergency Action

The most severe outcome documented in regulatory information is acute renal failure, which can result from the precipitation of Aciclovir crystals in the kidney tubules. Severe CNS symptoms like encephalopathy and coma have also been described. Due to these risks, immediate medical attention is required for suspected overdosage. Emergency services must be contacted if the affected person collapses, has a seizure, cannot be awakened, or has trouble breathing.


Management and Special Considerations

No specific antidote is known for Ciclox overdose; treatment is symptomatic and supportive. Regulatory documents state that haemodialysis significantly enhances drug removal and may be considered. Elderly patients and individuals with pre-existing renal impairment are noted as being at an increased risk of severe neurological side effects in an overdose situation, requiring closer observation.

Therapeutic Uses of Ciclox

What Ciclox Treats: Main Uses and Benefits

Ciclox (Aciclovir) is a medicine generally relevant for managing viral infections caused by the Herpes Simplex Virus (HSV) and Varicella-Zoster Virus (VZV). It is commonly used across conditions characterized by periods of heightened symptoms that require supportive management.

This medication is generally relevant for managing acute and recurrent episodes of cold sores, genital herpes, shingles, and chickenpox, and may be applied in complex cases involving systemic functional stress. The medicine supports the resolution of visible lesions and may contribute to easing the overall symptom load during the symptomatic episode.

“The medication is commonly used to help with symptom clusters that may become intense or disruptive, and may assist with maintaining a sense of stability when symptoms are more noticeable.”

It plays a role in managing symptoms related to physical discomfort and heightened neurological activity, like acute nerve pain, burning, and tingling. This use may assist with maintaining functional stability when symptoms are more noticeable and helps patients cope more steadily during symptomatic periods.


Quick Fact: Relief for Acute Symptoms

Property Description
Symptom Type Addressed Vesicular lesions, acute nerve pain, prodromal sensations
Common Clinical Scenarios Episodic treatment of cold sores, suppressive therapy for recurrent genital herpes, acute shingles management
Patient Benefit Focus Supports resolution of lesions, contributes to improved comfort, helps maintain functional stability

Regulatory References

  1. Acyclovir: MedlinePlus Drug Information

Eligibility and Restrictions for Use

Who Can and Cannot Use Ciclox?

The eligibility for Ciclox (Aciclovir) is strictly determined by regulatory documents, defining absolute prohibitions and conditional use requirements based on the patient profile.

Populations for Whom Use is Contraindicated

Use is strictly prohibited for patients with a documented hypersensitivity (allergy) to aciclovir, valaciclovir, or any component of the specific formulation. Use is also formally contraindicated for individuals with certain hereditary metabolic disorders, such as galactose or fructose intolerance, due to excipients in some oral tablet and suspension forms.

Populations Requiring Conditional Use

Use is classified as conditional and requires regulatory oversight and monitoring in specific groups:

  • Patients with Impaired Renal Function: Use is restricted and requires careful monitoring, as the medicine's clearance depends on kidney function.
  • Geriatric Patients (Older Adults): Require caution and potential consideration for adjustment due to the labeled higher plasma concentrations linked to age-related changes in renal function.
  • Pregnancy and Lactation: Eligibility is based on a risk assessment, with use recommended only when the potential benefits are documented to outweigh possible risks. The medicine is detected in breast milk.

Age-Related Eligibility

Age limitations vary by formulation: the topical cream is generally established for patients 12 years and older, while the intravenous formulation is typically restricted for use in neonates and infants (under three months) with severe infections.

What should I know about interactions with other medicines?

Interactions with other medicines and products

The official regulatory interaction profile for Ciclox (Aciclovir) is defined primarily by competition for the renal clearance pathway and specific pharmacodynamic effects. All documented interaction information is based strictly on authoritative regulatory prescribing documents.

Pharmacokinetic Exposure Modifications

Co-administration with certain medicines that compete for the active renal tubular secretion process can lead to increased systemic exposure. Substances such as Probenecid and Cimetidine are documented to reduce the kidney's clearance of Aciclovir, resulting in a higher plasma area under the curve (AUC). Similarly, co-administration with Mycophenolate Mofetil (MMF) affects the clearance of both Aciclovir and MMF’s inactive metabolite, indicating competition in the renal transport pathway.

Specific Interaction Constraints

  • Talimogene laherparepvec: This combination is officially categorized as one to be avoided due to a specific pharmacodynamic antagonism, which is documented to decrease the therapeutic effect of the co-administered drug.
  • Potentially Nephrotoxic Agents: Combining Ciclox with medicinal products classified as potentially nephrotoxic (e.g., NSAIDs or aminoglycosides) increases the shared risk of developing renal dysfunction.
  • Theophylline: Co-administration is formally documented to increase the area under the curve (AUC) of totally administered Theophylline by approximately 50%.

Food and Timing Rules

Official regulatory documents indicate that there are no known interactions between Ciclox and food, drinks, or alcohol. Furthermore, regulatory labels do not specify any mandatory timing separation rules for administering Ciclox with other medicines.

Mechanism of Action

How Ciclox Works: Mechanism of Action


Selective Viral Enzyme Activation

The mechanism of Ciclox hinges on a unique process where the inactive drug is specifically converted into its potent form by the Viral Thymidine Kinase ( vTK) enzyme, which is produced only by the target herpes viruses. This initial, rate-limiting step results in a high concentration of the active drug, Aciclovir Triphosphate ( ACV-TP), predominantly inside infected cells, which limits the potential for significant activity in uninfected host cells.


Obligate DNA Synthesis Termination

Once activated, the drug acts as a decoy for the natural DNA building block ( dGTP), competitively binding to and inhibiting the virus’s reproductive machinery, Viral DNA Polymerase ( vDNAP). When ACV-TP is incorporated into the viral DNA strand, it lacks the chemical structure necessary for further extension, causing an irreversible and obligate chain termination of the genome synthesis. This action fundamentally limits the virus’s ability to produce new infectious particles, which represents the primary physiological effect of the mechanism.


Replication-Dependent Mechanism

The entire anti-viral action of Ciclox is contingent upon the virus being in an active, replicating state where the vTK enzyme is readily available. Since vTK expression is minimal or absent when the virus is latent (non-replicating) within nerve ganglia, the drug cannot be activated against these dormant reservoirs. This mechanistic limitation results in the acute inhibition of viral growth rather than the physiological eradication of the virus from the body.

Dosage and Administration Information

How Ciclox is Used

The usage of Ciclox (Aciclovir) is defined by its approved route, precise dosing, and duration, which are outlined in prescribing information. The medication is available for administration by oral intake (tablets, capsules, suspension), topical application (cream/ointment), and intravenous (IV) infusion for more severe systemic infections.


Dosing and Frequency Patterns

Specific patterns exist for oral use. For treating acute episodes, the dose is commonly administered in a high-frequency regimen, such as 200 mg or 800 mg taken up to five times daily. Conversely, for chronic suppressive therapy, a maintenance dose is often set at 400 mg administered only twice daily. IV administration, typically reserved for hospital settings, is based on patient weight and is usually given every 8 hours.

Usage Pattern Typical Adult Oral Dose/Frequency Duration Pattern
Acute Course 200 mg or 800 mg five times daily 5 to 10 days
Suppressive Course 400 mg twice daily Up to 12 months, followed by re-evaluation

Administration Requirements

Oral Ciclox may be taken with or without food and should be accompanied by sufficient fluid intake to ensure adequate hydration. For IV administration, the solution must be diluted and infused slowly over a period of at least one hour to minimize renal effects. Furthermore, dose adjustment is a required procedural step for all routes of administration when the patient has documented renal impairment, a consideration that is especially relevant for older adults.

Recent Clinical Evidence

Ciclox: Recent Clinical Evidence

Evidence for Use in Recurrent Genital Herpes

The research for managing recurrent genital herpes relies on short-term Randomized Controlled Trials (RCTs) and systematic reviews, which examined outcomes related to episodic changes such as lesion resolution time and viral shedding duration. For managing frequent outbreaks, long-term RCTs were conducted for suppressive therapy. Studies reported measurements where the incidence and frequency of recurrence recorded in one group were lower than those recorded in a comparator group. However, long-term functional stability data are still emerging, and research on topical formulations reported measurements that were often described as less consistent than those observed with the oral dose.

Evidence for Use in Acute Shingles (Herpes Zoster)

Research for acute shingles is based on double-blind RCTs, primarily in adults and older adults. These studies measured the rate of skin lesion resolution and the duration of acute pain, alongside the subsequent incidence of Post-Herpetic Neuralgia (PHN). Studies reported measurements where the time required for skin lesion crusting recorded in the actively monitored group was less than in the comparator group. Importantly, findings related to the prevention of prolonged nerve pain (PHN) at specific follow-up milestones were variable and inconsistent across various systematic reviews.

Evidence in Special Subgroups and Uncertainties

Ciclox was evaluated in specific populations, including otherwise healthy children with chickenpox and older adults with shingles. For severe systemic infections, evidence is primarily limited to case series and cohort studies, as RCTs are often not feasible. This non-randomized data prevents establishing robust statistical certainty. A major research gap is the inconsistent evidence regarding PHN prevention, and follow-up durations were limited in many primary trials, meaning that long-term effects on functional recovery are not fully established.

Key Studies & References

  1. Does Treatment of Acute Herpes Zoster Prevent or Shorten Postherpetic Neuralgia? A Systematic Review of the Literature
  2. DailyMed Label: ACYCLOVIR tablet (Summary of Clinical Trials and Indications)

Frequently Asked Questions (FAQ)

Common questions about Ciclox (FAQ)


Q: What is Ciclox mainly used for, in simple terms?

A: Ciclox is classified as an antiviral drug. Official regulatory documents indicate that its primary use is to treat infections caused by herpes viruses, which include the herpes simplex virus (HSV) and the varicella-zoster virus (VZV), responsible for shingles and chickenpox.


Q: Is Ciclox a type of antibiotic, anti-inflammatory, or something else?

A: Regulatory classification describes Ciclox as an antiviral agent, specifically a purine nucleoside analog. This means its mechanism is highly targeted to inhibit the virus directly, unlike an antibiotic (which targets bacteria) or an anti-inflammatory drug.


Q: Can Ciclox be taken by teenagers or children?

A: Yes, official regulatory documents confirm that specific dosing regimens and indications are established for the treatment of certain herpes virus infections in pediatric patients, including infants and children. Eligibility is determined by a prescribing healthcare provider based on the specific infection.


Q: Are there any common foods or drinks that should be avoided while taking Ciclox?

A: Official prescribing information indicates that the drug can be taken with or without food. There are no specific foods or drinks listed for absolute avoidance; however, official guidance emphasizes the importance of sufficient fluid intake to support proper kidney function during administration.


Q: What kind of side effects are most often reported with Ciclox?

A: Commonly reported side effects in official documents include headache, dizziness, nausea, vomiting, abdominal pain, and diarrhea. Many common side effects are described as transient and may lessen as treatment progresses.


Q: Is it common to feel tired or dizzy after starting Ciclox?

A: Yes, official documents list both dizziness and fatigue or sleepiness as adverse reactions that are commonly reported by patients taking the drug. This information is noted in the official prescribing labels.


Q: Can someone with kidney or liver problems use Ciclox?

A: The drug is eliminated primarily by the kidneys, and regulatory documents specify that careful consideration of dosage adjustment is necessary for individuals with impaired renal (kidney) function. Information regarding required dose adjustment for primary liver problems (hepatic impairment) is not consistently detailed in major regulatory labels.


Q: Is Ciclox known to cause any long-term health issues?

A: Official documents support long-term use, such as for suppressive therapy which can last up to 12 months, with documented safety profiles. The guidelines for long-term use include provisions for regular clinical re-evaluation of the patient's condition and treatment. Potential for adverse renal effects during administration is a key factor considered in regulatory warnings.


Q: Can Ciclox be taken with vitamin supplements?

A: Official patient information highlights a need for caution with unproven supplements and herbal remedies. This is because there is frequently insufficient regulatory data available to confirm the safety or potential for interaction when combining them with prescription medications like this drug.


Q: What is the risk of having an allergic reaction to Ciclox?

A: Allergic reactions are a possible adverse effect. Official prescribing information lists rare but serious reactions, such as anaphylaxis (a severe, life-threatening allergic reaction) or angioedema (swelling beneath the skin), as potential risks.


Q: How long does Ciclox stay in your system after stopping treatment?

A: Regulatory data on the drug's metabolism show that the mean elimination half-life is approximately 2.5 to 3 hours in adults with normal kidney function. The half-life refers to the time it takes for the concentration of the drug in the body to decrease by half.


Q: Is Ciclox available as a generic medicine?

A: Yes, the active substance, Aciclovir, is widely available in a variety of generic formulations in addition to the brand-name product.


Q: Are there any warnings about driving or operating machinery while on Ciclox?

A: Official patient guidance states that activities requiring full attention, such as driving, riding a bike, or operating machinery, should be avoided if the patient experiences central nervous system side effects like dizziness or confusion.


Q: Does Ciclox interact with alcohol, and what does the official guidance say?

A: While regulatory labels do not strictly forbid alcohol use, patient information guides often include a precautionary statement about limiting or avoiding excessive alcohol intake. This caution is primarily due to the potential for alcohol to increase or worsen certain side effects, such as headaches.


Q: Is Ciclox ever used for conditions other than its main approved purpose?

A: In addition to the officially approved uses, official sources sometimes mention that the drug is used in clinical practice to treat certain other conditions caused by the herpes virus. These are referred to as non-FDA-approved or off-label uses.


Q: Can Ciclox cause problems with sleeping?

A: Yes, official documents list difficulty sleeping as a potential side effect.


Q: What is the general success rate of Ciclox in clinical trials?

A: Clinical data supporting the use of the drug for suppressive therapy indicate that it significantly reduces the frequency of recurrences. Studies show that it reduces outbreaks by 70%–80% among individuals who have frequent episodes.


Q: Is Ciclox habit-forming or addictive?

A: No, regulatory classification confirms that the drug is not a controlled substance and has no known potential for abuse or dependency.


Q: Who is considered 'ineligible' to use Ciclox according to the official documents?

A: The most common absolute contraindication listed in official documents is a known clinical hypersensitivity, meaning a severe allergy, to the drug itself or to its chemical derivative, valaciclovir.


Q: Are there any specific safety warnings listed for older adults using Ciclox?

A: Regulatory documents note that the drug's clearance tends to decrease in older adults due to age-related changes in kidney function. For this reason, regulatory guidance emphasizes the need for special attention to proper dosage and maintaining sufficient fluid intake in this population.


Q: How does the FDA classify the safety profile of Ciclox?

A: The FDA classifies the drug's safety profile for use during pregnancy as Category B. This classification indicates that animal reproduction studies have generally not shown a risk to the fetus, but well-controlled studies in pregnant women are not available.


Q: If I am taking an herbal supplement, is there a chance it will interact with Ciclox?

A: Official patient information highlights a need for caution, stating that there is often not enough testing or data available to confirm the safety of taking herbal remedies or supplements with the drug, due to the potential for unknown drug interactions.


Q: Does Ciclox require any special monitoring or blood tests?

A: Regulatory guidance specifies that monitoring kidney function is particularly important, especially when the drug is administered intravenously or when co-administered with other medications that are known to affect the kidneys.


Q: Is it normal to have mild stomach upset when first taking Ciclox?

A: Yes, mild gastrointestinal effects such as nausea, vomiting, and diarrhea are listed among the commonly reported side effects. These effects are often noted as being more frequent when first starting the course of treatment.


Q: Is Ciclox generally well-tolerated by most people?

A: The drug is generally described in official texts as well tolerated. However, the official prescribing information does list a range of both common and rare side effects that patients may wish to review.


Q: Can Ciclox be used safely during pregnancy or breastfeeding, according to regulatory data?

A: The drug's regulatory profile suggests that use during pregnancy may be considered when the prescribing physician determines the benefit justifies the potential risk. Official data also indicates that only small amounts pass into breast milk, and use is generally considered compatible with breastfeeding.


Q: What are the most serious possible side effects listed for Ciclox?

A: Serious, but rare, side effects listed in official documents include acute renal failure (sudden kidney problems), central nervous system effects (such as confusion, hallucinations, or seizures), and serious allergic reactions like angioedema.


Q: Is it true that Ciclox can affect mood or mental state?

A: Yes, official documents list potential changes in mood and mental state, including agitation, confusion, hallucinations, and tremors. These are reported as rare but serious adverse effects affecting the nervous system.


Q: How does Ciclox affect the immune system?

A: The drug's mechanism is highly selective, meaning its primary action is limited to interfering with viral enzymes within infected cells. It is used in both immunocompetent and immunocompromised patients, indicating its targeted effect against the virus rather than a broad effect on the human immune system.


Q: Why do official documents mention 'Ciclox and light sensitivity'?

A: Official documents list photosensitivity, where the skin becomes sensitive to light, as a possible side effect of the drug. The information commonly suggests that sun protection measures may be considered.


Q: Are there any long-term research studies on the use of Ciclox?

A: Yes, long-term safety and efficacy data have been documented for patients receiving daily suppressive therapy, which can last for a year or more. This data supports the drug's approved use for chronic management.


Q: What does the official label say about stopping Ciclox treatment?

A: Official use guidelines for chronic suppressive therapy state that treatment is typically followed by a re-evaluation period after a set time. This procedure is designed to determine the necessity of continuing or stopping the medication.


Q: Is Ciclox a controlled substance?

A: No, the drug is not categorized as a controlled substance under regulatory scheduling.


Q: What are the typical storage conditions described for Ciclox?

A: Regulatory documents describe typical storage conditions for oral forms as being at room temperature. The information often specifies keeping the drug in the original container to protect it from moisture and light.

How should Ciclox be stored and disposed of?

The storage and disposal of Ciclox (Aciclovir) must follow strict regulatory guidelines to preserve its quality and ensure safety.

Storage Requirements

Ciclox tablets and capsules must be stored at Controlled Room Temperature, which is 20 C to 25 C (68 F to 77 F). The product must be protected from moisture and light and should not be frozen or exposed to excess heat. Keep the medication in its original container, ensure the container is tightly closed, and store it out of the reach and sight of children.

Stability and Disposal

The oral suspension form must be discarded after 14 days of mixing. Expired or unused medication must be disposed of using an official drug take-back program. If a take-back program is unavailable, the product should be mixed with an unappealing substance, sealed in a bag, and placed in the household trash, as specified by regulatory disposal protocols.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Ciclox found in:

A-Z Index: